|
Destination
Europe
Severe price erosion and intense competition in the US market
has prompted Indian pharma to test European waters by acquisitions,
marketing, licensing and tie-ups. Both big and mid-size companies
are making a beeline to tap the European opportunity, learns
Sapna Dogra.
Talk
about India, but invest in China?
The Indian pharmaeutical industry seems set to emerge from
the confines of the generics market in which it has largely
positioned itself and could soon become a major global player.
Pharma
treads the nutra path
Let thy food be thy medicine and thy medicine be thy food.
This is what the Father of Medicine, Hippocrates said about
the thin line between food and medicine. Looks like the line
does not exist anymore as many pharma companies are going
the nutra way. Katya Naidu explores
Bangalore
gears up for biotech revolution
Katya Naidu reports on Bangalore Bio 2006.
NPIL
to acquire Pfizer's UK facility
Nicholas Piramal India Limited (NPIL) announced its intention
to acquire the manufacturing facility of Pfizer, located at
Morpeth, Northumberland, UK.
GSK
strengthens its Asian presence
GlaxoSmithKline (GSK) is all set to strengthen its presence
in Asia with the establishment of its first vaccine manufacturing
plant in Singapore.
Biocon
to launch new cancer drug
A new cancer drug is on the way from Biocon. An announcement
on these lines was made at the inauguration of Biocon Park,
India's largest integrated biotech hub.
Chiron
Panacea Vaccines goes IT savvy
SQL Star International has entered into an agreement with
Chiron Panacea Vaccines PVT for managing their IT based applications.
|
